Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alanyl-glutamine Supplementation in C. Difficile Infection
NCT04305769Phase 2Recruiting
- Sponsor
- University of Virginia
- Start
- Jun 2021
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alanyl glutamine in Clostridioides difficile infection (CDI), sponsored by University of Virginia. Started Jun 2021; status: recruiting.
02
Drugs
alanyl glutamine
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT04305769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305769.